BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation

  • Jang, Dahye (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Baek, Yu Mi (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Park, Hanna (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Hwang, Yeo Eun (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Kim, Dong-Eun (Department of Bioscience and Biotechnology, Konkuk University)
  • Received : 2017.08.22
  • Accepted : 2017.09.02
  • Published : 2018.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Non-small-cell lung cancer (NSCLC) is commonly caused by a mutation in the epidermal growth factor receptor (EGFR) and subsequent aberrant EGFR signaling with uncontrolled kinase activity. A deletion mutation in EGFR exon 19 is frequently observed in EGFR gene mutations. We designed a DNAzyme to suppress the expression of mutant EGFR by cleaving the mutant EGFR mRNA. The DNAzyme (named Ex19del Dz) specifically cleaved target RNA and decreased cancer cell viability when transfected into gefitinib-resistant lung cancer cells harboring EGFR exon 19 deletions. The DNAzyme decreased EGFR expression and inhibited its downstream signaling pathway. In addition to EGFR downregulation, Ex19del Dz containing CpG sites activated Toll-like receptor 9 (TLR9) and its downstream signaling pathway via p38 kinase, causing an immunostimulatory effect on EGFR-mutated NSCLC cells. Thus, dual effects of this DNAzyme harboring the CpG site, such as TLR9 activation and EGFR downregulation, leads to apoptosis of EGFR-mutated NSCLC cells.

Keywords

References

  1. Sharma SV, Bell DW, Settleman J and Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169-181 https://doi.org/10.1038/nrc2088
  2. Ciardiello F and Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7, 2958-2970
  3. Tam IY, Chung LP, Suen WS et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12, 1647-1653 https://doi.org/10.1158/1078-0432.CCR-05-1981
  4. Riely GJ, Politi KA, Miller VA and Pao W (2006) Update on epidermal growth factor receptor mutations in nonsmall cell lung cancer. Clin Cancer Res 12, 7232-7241 https://doi.org/10.1158/1078-0432.CCR-06-0658
  5. Paez J, Janne P, Lee J et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 https://doi.org/10.1126/science.1099314
  6. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73 https://doi.org/10.1371/journal.pmed.0020073
  7. Dass CR, Choong PF and Khachigian LM (2008) DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 7, 243-251
  8. Kim JE, Yoon S, Choi BR et al (2013) Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinibresistant BCR-ABL leukemic cells. Leukemia 27, 1650-1658 https://doi.org/10.1038/leu.2013.60
  9. Santoro S and Joyce G (1997) A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 94, 4262-4266 https://doi.org/10.1073/pnas.94.9.4262
  10. Khachigian L (2000) Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 106, 1189-1195 https://doi.org/10.1172/JCI11620
  11. Silverman SK (2008) Catalytic DNA (deoxyribozymes) for synthetic applications-current abilities and future prospects. Chem Commun (Camb), 3467-3485
  12. Appaiahgari MB and Vrati S (2007) DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol Ther 15, 1593-1599 https://doi.org/10.1038/sj.mt.6300231
  13. Bessis N, GarciaCozar FJ and Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 Suppl 1, S10-17 https://doi.org/10.1038/sj.gt.3302364
  14. Akira S, Uematsu S and Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124, 783-801 https://doi.org/10.1016/j.cell.2006.02.015
  15. Aderem A and Ulevitch R (2000) Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 https://doi.org/10.1038/35021228
  16. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas R and Wagner H (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32, 1958-1968 https://doi.org/10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U
  17. Wagner EF and Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549 https://doi.org/10.1038/nrc2694
  18. Lee KJ, Kim YK, Krupa M et al (2016) Crotamine stimulates phagocytic activity by inducing nitric oxide and TNF-$\alpha$ via p38 and $ NF{\kappa}$-B signaling in RAW 264.7 macrophages. BMB Rep 49, 185-190 https://doi.org/10.5483/BMBRep.2016.49.3.271
  19. Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63, 975-983 https://doi.org/10.1016/j.jaad.2009.12.052
  20. da Rosa MR, Falcao AS, Fuzii HT et al (2014) EGFR signaling downstream of EGF regulates migration, invasion, and MMP secretion of immortalized cells derived from human ameloblastoma. Tumour Biol 35, 11107-11120 https://doi.org/10.1007/s13277-014-2401-3
  21. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5, 471-484 https://doi.org/10.1038/nrd2059
  22. Droemann D, Albrecht D, Gerdes J et al (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6, 1 https://doi.org/10.1186/1465-9921-6-1
  23. Latz E, Verma A, Visintin A et al (2007) Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8, 772-779 https://doi.org/10.1038/ni1479
  24. Tsujimura H, Tamura T, Kong HJ et al (2004) Toll-Like Receptor 9 Signaling Activates NF-${\kappa}B$ through IFN Regulatory Factor-8/IFN Consensus Sequence Binding Protein in Dendritic Cells. J Immunol 172, 6820-6827 https://doi.org/10.4049/jimmunol.172.11.6820